{"nctId":"NCT00656513","briefTitle":"Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer","startDateStruct":{"date":"2008-09"},"conditions":["Head and Neck Cancer","Xerostomia"],"count":196,"armGroups":[{"label":"Pilocarpine: Phase III","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pilocarpine"]},{"label":"ALTENS: Phase III","type":"EXPERIMENTAL","interventionNames":["Procedure: ALTENS"]},{"label":"ALTENS: Phase II","type":"EXPERIMENTAL","interventionNames":["Procedure: ALTENS"]}],"interventions":[{"name":"Pilocarpine","otherNames":["pilocarpine hydrochloride"]},{"name":"ALTENS","otherNames":["acupuncture-like transcutaneous electrical nerve stimulation"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of head and neck cancer\n\n  * No clinical evidence of disease recurrence by ear, nose, and throat exam with a nasopharyngeal scope, if indicated, 8 weeks prior to registration\n* Completed radiotherapy (i.e., standard or intensity-modulated radiotherapy) with or without chemotherapy ≥ 3 months and up to 2 years prior to study entry\n\n  * Grade 1-2 radiotherapy-induced xerostomia according to the NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.3.0 and the dry mouth/salivary gland xerostomia scale\n  * Must have evidence of residual salivary function with unstimulated (basal) whole salivary production ≥ 0.1 ml/min after having refrained from eating or drinking oral fluid for 2 hours\n* No patients with normal saliva production (i.e., no salivary gland changes or no xerostomia)\n* No history of serious adverse events after prior treatment with and discontinuation of pilocarpine\n* No chronic lymphocytic leukemia\n\nPATIENT CHARACTERISTICS:\n\n* See Disease Characteristics\n* Zubrod performance status of 0-2\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other invasive malignancy except non-melanomatous skin cancer or cancer from which the patient has been disease-free for at least 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix)\n* No concurrent contraindications to pilocarpine (e.g., uncontrolled asthma, miosis, or hypersensitivity)\n* No severe, active co-morbidity, including any of the following:\n\n  * Unstable cardiac disease or requirement for a pacemaker in-situ\n  * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months\n  * Transmural myocardial infarction within the past 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration\n  * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\n* No Sjögren syndrome\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* At least 2 weeks since prior pilocarpine or cevimeline and no concurrent use for ophthalmic or non-ophthalmic indications\n* No concurrent regular medications that induce xerostomia (e.g., tricyclic antidepressants, antihistamines with anticholinergic effects, or narcotics)\n* No concurrent oral stimulating agents or salivary gland medical stimulants","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Phase II: Treatment Compliance (Number of Compliant Patients)","description":"Patients completing at least 19 out of 24 ALTENS therapy sessions were categorized as compliant. Fleming's two-stage was used, assuming a successful target compliance rate of 80%, statistical power of 0.87, and a type I error rate of 0.13. If fewer than 9 of the first 13 patients were compliant, then treatment delivery will be deemed not feasible. If there were between 9-12 compliant patients, the second stage analysis would be required to determine feasibility of treatment delivery. If all 13 patients are compliant, treatment delivery will immediately be deemed feasible. The second stage analysis required at least 31 compliant out of 39 overall patients for the treatment delivery to be deemed feasible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null}]}]}]},{"type":"PRIMARY","title":"Phase III: Change From Baseline in Overall Xerostomia Burden at 9 Months","description":"Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":null},{"groupId":"OG001","value":"-0.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Phase II: Pecentage of Patients With Beneficial Treatment Response","description":"This secondary objective was to evaluate the effect of ALTENS treatment on overall radiation-induced xerostomia burden by looking at treatment response. Treatment response was determined by a reduction of at least 20% from baseline to 6 months in the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4. Higher scores indicate increased xerostomia burden. This scale has high reproducibility and sensitivity. For the first and second stage analyses, 4 and 10 patients, respectively, must respond to treatment in order to proceed to the phase III component.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Overall Xerostomia Burden at 4, 6, and 15 Months (Phase III)","description":"Xerostomia burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning.The score is the average of all responses of all domains and can range from 0 to 4, with higher scores indicating increased xerostomia burden. Change in xerostomia burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the xerostomia burden.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":null},{"groupId":"OG001","value":"-0.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":null},{"groupId":"OG001","value":"-0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Symptom Burden at 4, 6, 9 and 15 Months (Phase III)","description":"Symptom burden is measured by the University of Michigan Xerostomia Related Quality of Life Scale (XeQOLS). The XeQOLS is a validated patient-reported 15-item assessment scale with 4 domains: physical functioning,pain/discomfort, personal/psychologic functioning, and social functioning. The domain score is the average of all responses on a given domain and can range from 0 to 4, with higher scores indicating increased symptom burden. Change in symptom burden is calculated by subtracting the baseline score from the 9-month score such that a negative change indicates an improvement of the symptom burden.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null},{"groupId":"OG001","value":"-0.375","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"-0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":null},{"groupId":"OG001","value":"-0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.66","spread":null},{"groupId":"OG001","value":"-0.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"-0.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Stimulated Whole Salivary Production (WSP) at 4, 6, 9 and 15 Months (Phase III)","description":"Stimulated (citric acid primed) whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. Stimulation is elicited by asking patients to rinse 5 ml of 2% citric acid solution in the mouth for 15 seconds and then completely expectorating the citric acid. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":null},{"groupId":"OG001","value":"0.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Unstimulated Whole Salivary Production (WSP) at 4, 6, 9 and 15 Months (Phase III)","description":"Basal whole salivary production (WSP) was measured by expectoration weight, with one gram of saliva produced considered as one ml of saliva. WSP is expressed in ml/min calculated by dividing the measured weight or volume of WSP by five. Procedure: Patients refrain from eating, drinking, and smoking at least two hours prior to each measurement. For each measurement, patients are asked to expectorate continuously into a pre-weighed dry plastic container over a 5-minute period without swallowing. The collected saliva with the plastic container will be weighed (total weight) immediately after each collection. The total weight minus the weight of the container is the weight or volume of whole saliva collected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.02","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.056","spread":null},{"groupId":"OG001","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":null},{"groupId":"OG001","value":"0.192","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life (QOL) as Measured by the University of Washington Head and Neck Questionnaire (UWHNSS) Phase III","description":"The UWHNSS includes ten categories-pain, disfigurement, activity, recreation/entertainment, employment, eating, saliva, taste, speech, mucus/phlegm. Patient scores on the UWHNSS range from 0 to 100 with higher scores indicating declining quality of life. Change in total score was calculated by subtracting baseline from follow-up , thus a positive change score indicates a worsening while a negative change score indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.64","spread":null},{"groupId":"OG001","value":"-7.27","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":47},"commonTop":["Dry mouth","Sweating","Dysphagia","Headache","Fatigue"]}}}